C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC)

Historical Holders from Q4 2020 to Q3 2025

Symbol
CCCC on Nasdaq
CUSIP
12529R107
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
71.4M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
52.5M
Holdings value
$117M
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
95
Number of buys
47
Number of sells
-62
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Point72 Asset Management, L.P. 9.9% $50.3M 22.6M Point72 Asset Management, L.P. Oct 17, 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% $21M $21M 9.44M RA Capital Management, L.P. Oct 17, 2025
Bain Capital Life Sciences Fund II, L.P. 6.25% $13.5M 6.06M BCLS II Equity Opportunities, LP Oct 17, 2025
WASATCH ADVISORS LP 6.8% -33.6% $10.8M -$5.82M 4.85M -35.1% Wasatch Advisors LP Sep 30, 2025
MORGAN STANLEY 6.7% +26% $7.32M $1.42M 4.75M +24.1% Morgan Stanley Jun 30, 2025
ORBIMED ADVISORS LLC 5% -22.9% $7.92M -$2.41M 3.57M -23.4% OrbiMed Capital LLC Sep 30, 2025
BlackRock, Inc. 2.5% $2.71M 1.76M BlackRock, Inc. Jun 30, 2025

Institutional Holders of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 52.5M $117M -$3.49M $2.22 95
2025 Q2 54.7M $78.2M -$14.7M $1.43 102
2025 Q1 64.1M $103M -$12.6M $1.60 113
2024 Q4 64.4M $232M -$9.81M $3.60 113
2024 Q3 64.2M $366M +$21.1M $5.70 121
2024 Q2 60.9M $281M +$7.12M $4.62 114
2024 Q1 58.2M $475M +$91.2M $8.17 103
2023 Q4 85K $480K $5.65 1
2023 Q3 34.6M $64.3M +$59K $1.86 81
2023 Q2 34.1M $93.8M -$9.38M $2.75 93
2023 Q1 37.3M $117M -$15M $3.14 115
2022 Q4 39.1M $231M -$9.77M $5.90 109
2022 Q3 39.3M $345M -$2.39M $8.77 109
2022 Q2 38.8M $293M -$38.9M $7.54 105
2022 Q1 36.5M $886M +$12.9M $24.26 115
2021 Q4 34.9M $1.12B -$4.99M $32.20 114
2021 Q3 34.5M $1.54B +$109M $44.68 111
2021 Q2 31.7M $1.2B +$211M $37.84 106
2021 Q1 25.1M $926M +$92.3M $36.99 82
2020 Q4 22.2M $728M +$703M $33.13 73